跳到正文
原文
BioMarin· @BioMarin · X·· 19 天前精选AI 评分52
AI 导读

BioMarin 宣布与 GC Biopharma 和 Hanmi Pharm 签订全球独家授权协议,开发并商业化一款针对法布雷病的潜在下一代酶替代疗法。该在研长效药物目前处于 1/2 期临床试验阶段,有望成为法布雷病首个皮下给药的酶替代疗法。

推荐理由

BioMarin 通过授权引进获得法布雷病长效酶替代疗法的全球权益,读者可据此观察罕见病酶替代治疗向皮下给药演进的路径。

正文

Today we announced we have entered into an exclusive worldwide license agreement with GC Biopharma and Hanmi Pharm to develop and commercialize a potential next-generation enzyme replacement therapy for Fabry disease. The investigational long-acting medicine is currently being studied in a Phase 1/2 clinical trial and has the potential to be the first subcutaneous enzyme replacement therapy for Fabry disease.

Read more in our press release: http://ms.spr.ly/6018a0q26

来源:BioMarin · x.com